Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Selumetinib (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 16 Oct 2012 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
- 15 Mar 2011 New trial record